Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Acquisitions & Divestments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with -$161.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 436.95% to -$161.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was -$104.8 million, a 16.77% decrease, with the full-year FY2024 number at $79.4 million, changed N/A from a year prior.
  • Change in Acquisitions & Divestments was -$161.0 million for Q2 2025 at Day One Biopharmaceuticals, down from $161.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $171.9 million in Q3 2023 to a low of -$445.9 million in Q4 2023.
  • A 4-year average of $19.9 million and a median of $119.2 million in 2022 define the central range for Change in Acquisitions & Divestments.
  • Biggest YoY gain for Change in Acquisitions & Divestments was 759.58% in 2023; the steepest drop was 474.22% in 2023.
  • Day One Biopharmaceuticals' Change in Acquisitions & Divestments stood at $119.2 million in 2022, then tumbled by 474.22% to -$445.9 million in 2023, then skyrocketed by 76.49% to -$104.8 million in 2024, then tumbled by 53.59% to -$161.0 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Change in Acquisitions & Divestments are -$161.0 million (Q2 2025), $161.0 million (Q1 2025), and -$104.8 million (Q3 2024).